People
InMed Pharmaceuticals Incorporated names new Scientific Advisory Board member
14 January 2019 -

InMed Pharmaceuticals Incorporated (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced on Friday that it has named Dr Sazzad Hossain, PhD, MSc as a new member of its Scientific Advisory Board.

Dr Hossain has announced his retirement as chief scientific officer. Dr Eric C Hsu, PhD, vice president, Pre-Clinical Research & Development, will continue to lead the company's scientific R&D programs.

Dr Hossain said, 'InMed's continued success in developing cannabinoids to treat serious diseases is vital to me. Unfortunately, given recent personal health concerns, I wish to modify my role to that of a scientific advisor. I look forward to continuing my involvement with the entire team at InMed. I believe the Company is in a very strong position to advance important potential treatments to patients with high unmet medical needs.'

Login
Username:

Password: